# IMPT Dose Escalation for NSCLC (HyDose)

> **NCT06484491** · NA · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 87 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **RADIATION:** Dose-escalated intensity-modulated proton therapy (IMPT-74)
- **DRUG:** Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy
- **DRUG:** Immunotherapy: adjuvant durvalumab

## Key facts

- **NCT ID:** NCT06484491
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06484491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06484491, "IMPT Dose Escalation for NSCLC (HyDose)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06484491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*